STOCK TITAN

CARGO Therapeutics, Inc. - $CRGX STOCK NEWS

Welcome to our dedicated page for CARGO Therapeutics news (Ticker: $CRGX), a resource for investors and traders seeking the latest updates and insights on CARGO Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CARGO Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CARGO Therapeutics's position in the market.

Rhea-AI Summary
CARGO Therapeutics appoints Kapil Dhingra, M.B.B.S., a seasoned oncology leader, to its Board of Directors, bringing extensive clinical development experience in oncology and cell therapy. Dr. Dhingra's appointment strengthens the company's expertise as it advances its lead CAR T-cell therapy candidate, firi-cel (CRG-022).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
management
-
Rhea-AI Summary
CARGO Therapeutics, Inc. provided a business update and reported financial results for the quarter ending December 31, 2023. The potentially pivotal Phase 2 clinical study FIRCE-1 of firicabtagene autoleucel (CRG-022) is rapidly recruiting with 20 sites open, with interim results expected in 1H 2025. The Phase 2 trial aims to evaluate the efficacy and safety of firi-cel in patients with relapse or refractory large B-cell lymphoma after CD19-directed CAR T-cell therapy. CARGO highlighted successful private financing and IPO, raising $291.0 million in net proceeds, and being added to the Russell 2000® Index. Financially, the company had $405.7 million in cash and cash equivalents as of December 31, 2023, expecting to fund operations through 2025. Research and development expenses were $27.1 million for Q4 2023, with a net loss of $32.1 million for the same period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.98%
Tags
-
Rhea-AI Summary
CARGO Therapeutics, Inc. (CRGX) will participate in the 44th Annual Cowen Healthcare Conference to discuss cell therapies for cancer patients. Gina Chapman, the CEO, will join a panel on March 6, 2024, at 9:10 a.m. EST. The webcast will be available on CARGO's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.68%
Tags
conferences
Rhea-AI Summary
CARGO Therapeutics, Inc. (NASDAQ: CRGX) to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.58%
Tags
conferences
-
Rhea-AI Summary
CARGO Therapeutics, Inc. (Nasdaq: CRGX) reported business updates and financial results for Q3 2023. The company began a Phase 2 clinical trial of CRG-022, a potentially pivotal CAR T-cell therapy for R/R LBCL patients. CARGO also raised $291 million in an IPO, strengthened its leadership team, and entered into a lease agreement for lab and office space in San Carlos, California.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
CARGO Therapeutics, Inc.

Nasdaq:CRGX

CRGX Rankings

CRGX Stock Data

796.82M
19.63M
7.6%
93.69%
9.12%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
SAN MATEO